Dr. Robert Coleman on the Importance of BRCA Testing in Ovarian Cancer

Robert Coleman, MD
Published: Thursday, Aug 04, 2016



Robert Coleman, MD a professor in the department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.
 
In the past, the focus was on whether or not a patient was a germline carrier, and if they were, what that implication would be for their offspring, said Coleman.
 
In the recent years, with the development of PARP inhibitors, there is a much better understanding about how DNA repair happens. There is a whole homologous recombination deficiency area that's really exploded, said Coleman. That has furthered the use of novel drugs, like olaparib, which has already been approved in the BRCA mutation population.
 
It has now been determined that in the lower risk groups, the majority of patients that would be BRCA positive were not identified. Because of those factors, BRCA testing is now recommend at diagnosis.  
 
 


Robert Coleman, MD a professor in the department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.
 
In the past, the focus was on whether or not a patient was a germline carrier, and if they were, what that implication would be for their offspring, said Coleman.
 
In the recent years, with the development of PARP inhibitors, there is a much better understanding about how DNA repair happens. There is a whole homologous recombination deficiency area that's really exploded, said Coleman. That has furthered the use of novel drugs, like olaparib, which has already been approved in the BRCA mutation population.
 
It has now been determined that in the lower risk groups, the majority of patients that would be BRCA positive were not identified. Because of those factors, BRCA testing is now recommend at diagnosis.  
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x